Imatinib Liquid Dosage Forms for Consistent Patient Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of Imatinib mesylate are primarily in solid forms, lacking liquid dosage forms that offer stability, palatability, and bioequivalence to marketed tablets, posing challenges for patients with swallowing difficulties and requiring flexible dosage regimens.
Innovation Solution
Development of ready-to-use liquid dosage forms of Imatinib mesylate, including solutions, suspensions, and syrups, with specific excipients like glycerin, maltitol, and flavors, ensuring stability, palatability, and bioequivalence to marketed tablets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If solid dosage forms (tablets) are used for Imatinib mesylate, then manufacturing and storage are straightforward, but patient compliance deteriorates due to swallowing difficulties and lack of dosage flexibility
Solution Approach 1:
The patent changes the physical state parameter from solid (tablet) to liquid (syrup, solution, suspension) to improve patient compliance. This phase transition enables easier administration to pediatric and geriatric patients while maintaining dosage flexibility through adjustable liquid volumes.
Solution Approach 2:
The patent introduces liquid excipients (glycerin, maltitol, flavors, colors) as intermediaries to transform the solid Imatinib mesylate into palatable liquid dosage forms. These mediators mask the bitter taste and improve acceptability while maintaining drug stability and bioavailability.
2Adaptability or versatility
If liquid dosage forms are developed for Imatinib mesylate, then patient compliance and dosage flexibility improve, but formulation stability deteriorates due to potential degradation in liquid state
Solution Approach 1:
The patent employs stabilizing excipients as intermediaries to protect Imatinib mesylate from degradation in liquid form. These agents maintain pH balance, prevent oxidation, and ensure chemical stability throughout the shelf life while allowing dosage flexibility.
Solution Approach 2:
The patent creates a chemically inert liquid environment using stabilizing excipients that prevent reactive interactions between Imatinib mesylate and water or other components. This inert environment minimizes hydrolysis and oxidation, maintaining formulation stability.
3Reliability
If liquid dosage forms are prepared for Imatinib mesylate, then bioavailability can be enhanced, but manufacturing complexity increases due to precise formulation requirements
Solution Approach 1:
The patent optimizes concentration parameters of Imatinib mesylate and excipients to maximize bioavailability. By adjusting the liquid dosage form concentration and using bioavailability-enhancing excipients, the patent ensures reliable drug absorption while establishing standardized manufacturing protocols.
Solution Approach 2:
The patent designs the liquid dosage form with self-emulsifying or self-dissolving properties that enhance bioavailability without requiring complex manufacturing processes. The formulation automatically optimizes its physical state for absorption upon contact with gastrointestinal fluids.
4Object-affected harmful factors
If conventional solid formulations are used, then storage and handling are simple, but palatability and acceptability deteriorate due to bitter taste and difficulty in administration
Solution Approach 1:
The patent introduces flavoring agents, coloring agents, and sweetening excipients as intermediaries to mask the bitter taste of Imatinib mesylate. These mediators create a palatable liquid dosage form that is acceptable to pediatric and geriatric patients while maintaining simple storage and handling procedures.
Solution Approach 2:
The patent changes the physical form from solid tablet to liquid syrup or solution, fundamentally altering the sensory parameters of taste, texture, and appearance. This parameter change eliminates the bitter taste issue and improves overall acceptability.
Data Source
AI summary
Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for administration. Further, dispersion of Imatinib solid oral dosage forms may not administer correct and consistent dose of medicine every time. The present invention therefore provides liquid dosage forms of Imatinib which correctly and consistently administers correct dose of drug to the patients.